1843 related articles for article (PubMed ID: 31471138)
21. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
22. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
23. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Perez C; Gruber I; Arber C
Front Immunol; 2020; 11():583716. PubMed ID: 33262761
[TBL] [Abstract][Full Text] [Related]
24. [Advances of CAR-T cell therapy in treating colorectal cancer].
Chao Z; Liu W; Liu Y
Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1365-1379. PubMed ID: 38783803
[TBL] [Abstract][Full Text] [Related]
25. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
26. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Salinas RD; Durgin JS; O'Rourke DM
CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
[TBL] [Abstract][Full Text] [Related]
27. [Chimeric antigen receptor (CAR)-T cell therapy].
Sakoda Y; Tamada K
Nihon Rinsho; 2017 Feb; 75(2):281-287. PubMed ID: 30562865
[TBL] [Abstract][Full Text] [Related]
28. Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.
Ando Y; Siegler EL; Ta HP; Cinay GE; Zhou H; Gorrell KA; Au H; Jarvis BM; Wang P; Shen K
Adv Healthc Mater; 2019 Mar; 8(5):e1900001. PubMed ID: 30734529
[TBL] [Abstract][Full Text] [Related]
29. Altered cancer metabolism and implications for next-generation CAR T-cell therapies.
Ramapriyan R; Vykunta VS; Vandecandelaere G; Richardson LGK; Sun J; Curry WT; Choi BD
Pharmacol Ther; 2024 Jul; 259():108667. PubMed ID: 38763321
[TBL] [Abstract][Full Text] [Related]
30. From antibodies to living drugs: Quo vadis cancer immunotherapy?
Szöőr Á; Szöllősi J; Vereb G
Biol Futur; 2021 Mar; 72(1):85-99. PubMed ID: 34554498
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
Martínez Bedoya D; Dutoit V; Migliorini D
Front Immunol; 2021; 12():640082. PubMed ID: 33746981
[TBL] [Abstract][Full Text] [Related]
32. How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?
Schoenfeld AJ; O'Cearbhaill RE
Cancer J; 2021 Mar-Apr 01; 27(2):134-142. PubMed ID: 33750073
[TBL] [Abstract][Full Text] [Related]
33. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
Front Immunol; 2021; 12():782775. PubMed ID: 34790207
[TBL] [Abstract][Full Text] [Related]
34. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
Huang D; Miller M; Ashok B; Jain S; Peppas NA
Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
[TBL] [Abstract][Full Text] [Related]
35. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
[TBL] [Abstract][Full Text] [Related]
36. CAR-NK cell in cancer immunotherapy; A promising frontier.
Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
[TBL] [Abstract][Full Text] [Related]
37. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
Lee YH; Kim CH
Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
[TBL] [Abstract][Full Text] [Related]
38. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Qian L; Chen J; Wu X; Jing R; Sun J
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
40. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]